Abstract
IL-6 is a critical cytokine in acute phase response and involved in the pathogenesis of several chronic inflammatory diseases including cancer. Studies have highlighted that levels of IL-6 and its family members can be useful for diagnosis, prognosis of relapse-free survival and recurrence. IL-6 family cytokines have been identified as cancer biomarkers through screening of inflammatory mediators in different fluids including saliva, serum, and bronchoalveolar lavage fluid (BALF). IL-6 can be modulated by chemopreventive drugs, small molecules, monoclonal antibodies and immune checkpoint inhibitors. Unveiling the different sources of IL-6, the interaction between IL-6 and its cellular targets, the IL-6-dependent tumor resistance mechanisms, and the identification of novel regulators of IL-6 are some of the highly complex topics included in this review and their understanding could aid cancer biomarkers and therapy development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-17 |
| Number of pages | 8 |
| Journal | Cytokine and Growth Factor Reviews |
| Volume | 41 |
| DOIs | |
| State | Published - Jun 2018 |
Keywords
- Cancer biomarker
- Cytokine
- IL-6
- IL-6 family
- Immunoprevention
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Immunology and Allergy
- Immunology
- General Biochemistry, Genetics and Molecular Biology